Abstract
The use of antigen delivery systems is essential for inducing antitumor immune responses. Among these, virus-like particles (VLPs) increase the immunogenicity of coupled antigens to stimulate cellular and humoral immune responses. In particular, non-enveloped or capsid VLPs (cVLPs) are a promising antigen delivery system option due to their additional advantages of high production yields and low cost. This review summarizes the latest works on cVLPs in cancer vaccines, supporting cVLPs as a tumor antigen delivery system for immunotherapy and addressing some critical aspects of cVLP use such as production, assembly, decoration and immunization strategies, which can improve the effectiveness of cancer vaccines based on cVLPs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
